ASTRAZENECA – fin des tests : 14 / 02 / 2023

Source : US National Library of Medicine – ClinicalTrials.gov

https://clinicaltrials.gov/ct2/show/NCT04516746



https://clinicaltrials.gov/ct2/show/NCT04516746

COVID-19 Information

Public health information (CDC) | Research information (NIH) | SARS-CoV-2 data (NCBI) | Prevention and treatment information (HHS) | Español

NIH U.S. National Library of Medicine

ClinicalTrials.gov

Find Studies | About Studies | Submit Studies | Resources | About Site | PRS Login

Home > Search Results > Study Record Detail

Save this study

Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04516746

Recruitment Status : Active, not recruiting
First Posted : August 18, 2020
Last Update Posted : April 13, 2021

Sponsor:
AstraZeneca

Collaborator:
Iqvia Pty Ltd

Information provided by (Responsible Party):
AstraZeneca

Study Details | Tabular View | No Results Posted | Disclaimer | How to Read a Study Record

Study Description

Go to

Brief Summary:
The aim of the study is to assess the safety, efficacy, and immunogenicity of AZD1222 for the prevention of COVID-19.

Condition or disease	Intervention/treatment	Phase
COVID-19	Biological: AZD1222	Phase 3
SARS-CoV-2	Biological: Placebo	

Detailed Description:
The COVID-19 pandemic has caused major disruption to healthcare systems with significant socioeconomic impacts. Currently, there are no specific treatments available against COVID-19 and accelerated vaccine development is urgently needed. A safe and effective vaccine for COVID-19 prevention would have significant public health impact.

Study Design

Go to

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	32459 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Intervention Model Description:	Participants are assigned to one of two or more groups in parallel for the duration of the study.
Masking:	Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:	Double Blind: two or more parties are unaware of the intervention assignment.
Primary Purpose:	Treatment
Official Title:	A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults, to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19
Actual Study Start Date :	August 28, 2020
Actual Primary Completion Date :	March 5, 2021
Estimated Study Completion Date :	February 14, 2023